WHY IT MATTERS: Patients who use cannabis regularly and are concerned about long-term brain health now have large-scale data to discuss with their physician, though the findings underscore the importance of individualized conversations rather than blanket reassurance or alarm. CLINICAL OVERVIEW: Research drawing on large biobank datasets has examined whether cannabis use is associated with measurable changes in brain aging trajectories. The findings suggest a nuanced picture in which cannabis users may show some initial differences in brain age metrics, but the relationship between cannabis exposure and long-term neurological aging is not straightforwardly harmful or protective.
Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online
WHY IT MATTERS: Patients who use cannabis heavily should know that research is actively examining how cannabis use disorder compares to other substance use disorders in terms of real-world psychiatric risks, which may affect how clinicians screen and counsel them going forward. CLINICAL OVERVIEW: Research comparing cannabis use disorder to other substance use disorders is an important area of inquiry because it helps clinicians understand the relative psychiatric burden associated with problematic cannabis use in the context of a rapidly changing legal and cultural landscape. Propensity-score-matched study designs are valuable here because they attempt to control for the many confounding variables that make substance use populations inherently difficult to compare fairly.
Endocannabinoid System Research: Cannabis & Autism Risk
Clinical Takeaway Children exposed to cannabis during the peripregnancy period showed associations with behavioral and developmental differences in offspring, with effects varying based on whether children had ASD symptoms. These findings suggest...
Endocannabinoid System & GLP-1 Receptor Mental Health Evidence
Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied for their potential causal effects on ten common mental health conditions using genetic analysis data. The findings...
Cannabinoid Clinical Trials: Cannabis Intervention in Teens
Clinical Takeaway Tailored cannabis prevention messaging that first addresses and refutes adolescents’ negative reactions to anti-cannabis appeals, then delivers a third targeted communication, shows promise as a more effective approach than one-size-fits-all...
Endocannabinoid System & Maternal Cytokines: Clinical Research
Clinical Takeaway Cannabis use during pregnancy is associated with measurable suppression of key immune signaling proteins (cytokines) in the mother’s bloodstream, findings confirmed through urine-verified exposure. Because the immune system plays a...
`Cannabinoid Clinical Trials: Cannabis-Induced Psychosis Risk`
Clinical Takeaway A significant portion of patients diagnosed with cannabis-induced psychosis go on to develop a primary psychiatric disorder such as schizophrenia spectrum disorder or bipolar disorder. Clinicians should treat cannabis-induced psychosis...
Cannabinoid Formulations for Anxiety and Tourette Syndrome
Clinical Takeaway Cannabinoid formulations, particularly CBD-containing products, show measurable reductions in anxiety symptoms across multiple study designs, though effect sizes and optimal dosing vary by condition and formulation. Evidence for Tourette syndrome...
Endocannabinoid System Research: Cannabis & HIV Smoking
Clinical Takeaway Digital therapeutics tailored to people living with HIV show promising feasibility and acceptability as a scalable approach to smoking cessation in this high-risk population. Tobacco use remains a leading driver...
Cannabidiol for Lennox-Gastaut: Clinical Trial Evidence
Clinical Takeaway Pharmaceutical-grade cannabidiol (Epidiolex) reduced drop seizure frequency in Lennox-Gastaut syndrome patients at thresholds below the traditional 50% benchmark, with caregiver-reported outcomes confirming that even smaller reductions translated to meaningful real-world...